Search results

Early-phase drug development is a complex process. Discover how Altasciences, as an integrated CRO/CDMO, alleviates the challenges and reduces risks.

Can the drug development industry change for the better? We dive into the obstacles and inefficiencies of the traditional outsourcing paradigm, and discuss how Altasciences offers an alternative to help sponsors safely accelerate their R&D.

In Issue 7 of The Altascientist, we discuss how age, biological sex, genetics, and drug-drug interactions can affect drug metabolism and outcomes.

This Q&A with Dr. Norbert Makori and Pierre Jolicoeur reveals insights on preclinical gene therapy studies and capabilities at Altasciences’ site in Seattle